IMMEDIATE Therapeutics
Research - Boston, Massachusetts, United States
IMMEDIATE Therapeutics Employees
IMMEDIATE Therapeutics Details
IMMEDIATE Therapeutics is a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to minimize heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS), the most common cause of death and morbidity across the world. IMMEDIATE: Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care IMT-358: First-in-class product providing metabolic protection to minimize cardiac damage and instability during acute coronary syndromes (ACS)Phase 2 Completed: Trial showed treatment associated reduction in infarct size by 80%; and reduced odds of cardiac arrest/mortality by over 50%Planned Phase 3 Study: Risk Mitigated 3 Year Study in the US and EU with 1600 patients set to begin Q4 2021Single Pivotal Phase 3 under FDA's Special Protocol AssessmentPotential Accelerated Approval (900 patients – 1 year)Granted FDA Breakthrough DesignationIMT-358 designated as a Biologic, so eligible for BLA with 12-year market protection at end of trialBlockbuster potential with global market estimates of $25B by 2035; first mover advantageStrong leadership and advisory team of world-renowned emergency cardiology experts & biotech executivesRaised over $40M in non-dilutive funding – Now seeking $100M in first ever equity funding to secure global approval of first indication in ACS with potential for additional indications in the future
IMMEDIATE Therapeutics Technologies
Email Providers
Gmail
CMS
WordPress.org
Fonts
Google Font API
Other
Microsoft Office 365
Hosting
Flywheel